PET with FDG May Predict Outcomes in Triple-Negative Breast Cancer

Article

Positron emission tomography with 18F-FDG during chemotherapy can help predict a patient’s response to therapy.

Positron emission tomography with 18F-FDG during chemotherapy for triple-negative breast cancer can help predict a patient’s response to therapy.

That’s according to an article published in the February issue of the Journal of Nuclear Medicine that examined the imaging method’s use to gauge active tumor metabolism during treatment.

Researchers in France recruited 20 patients with triple-negative breast cancer, an aggressive tumor which makes up 15 percent of invasive breast cancers. Patients underwent PET imaging with 18F-FDG at the start of their chemotherapy regimen. This exam was repeated after their second cycle of chemotherapy to gauge how metabolically active the tumors were. This information was then used to gauge the patients’ predicted therapy response and prognosis.

Researchers found that at the point of surgery, chemotherapy was completely successful in six patients and the other 14 had remaining tumors. Patients with less than a 42 percent decrease in 18F-FDG uptake at cycle two of their treatment still had residual tumor, with a high risk of relapse within two years.

Investigation into using this approach is still early, however the researchers are hopeful. “If these findings are confirmed by other teams, interim 18F-FDG-PET/CT could become a major tool for early response assessment of this aggressive cancer, similar to the role that 18-FDG plays in assessing aggressive lymphomas,” said one of the authors, David Groheux, MD, a principal researcher in the department of nuclear medicine at Saint-Louis Hospital in Paris, France.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.